PRESS RELEASE - NEPHRAT
Exocell is pleased to release news of research concerning Nephrat:
Exocell, a Philadelphia company specializing in diagnostic products relating to diabetes and its complications, reports on literature survey establishing its rat microalbuminuria assay, Nephrat II, as the method of choice for assessing renal injury and response to therapy in diabetic rats.
Nephrat is among a range of clinical and investigative diagnostic products developed and marketed by Exocell that accurately and specifically measure analytes in biological fluids and provide information on the course of diabetes and risk for complications.
Nephrat is an immunospecific assay that measures the amount of urinary albumin, an established marker of kidney dysfunction, in rodent models of diabetes and of other kidney diseases. Since its commercial introduction, Nephrat has gained worldwide recognition by scientists in academic and pharmaceutical sectors engaged in research on the underlying causes and potential treatment of kidney injury in diabetes and other diseases.
Results of scientific investigations describing use of Nephrat have been published in such diverse peer-reviewed journals as Cell Biochemistry Biophysics, Diabetes, and American Journal of Renal Physiology.
See select publications.
See also Exocell news about:
© 2012 Exocell Inc.